Press release
 
Novo Nordisk today announced that the European Commission has granted marketing authorisation for Fiasp® for the treatment of diabetes in adults.
 
The authorisation covers all 28 European Union member states.
 
Fiasp® is the brand name for fast-acting insulin aspart. Fiasp® provides improved mealtime and overall glucose control with a similar safety profile versus NovoRapid®. “Fiasp® is a new-generation mealtime insulin; it is an innovative faster formulation of insulin aspart that more closely mimics the physiological insulin response around meals.
 
The incremental benefits with Fiasp® are comparable to those observed for the last generation of mealtime insulins when introduced more than a decade ago”, said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.
 
Fiasp® will be available in vial, Penfill® and FlexTouch® pen.
 
Novo Nordisk expects to launch Fiasp® in the first European countries in the first half of 2017.
 
About Fiasp®
Fiasp® (fast-acting insulin aspart) is an ultra-fast rapid-acting insulin now approved in Europe that improves control of postprandial glucose (PPG) excursions and has been developed for the treatment of people with type 1 and type 2 diabetes, as well as for pump treatment.
 
Fiasp® is insulin aspart (NovoRapid®) in a new formulation, in which two new excipients have been added to ensure earlier, greater and faster absorption, thereby providing earlier insulin action. The review of Fiasp® was based on the onset programme, a phase 3 clinical programme comprising of four trials encompassing more than 2,100 people with type 1 and type 2 diabetes.
 
Fiasp® also received marketing authorisation from Health Canada on 6 January 2017
 
Nyhetsinfo
www red DiabetologNytt
FacebookTwitterLinkedinGoogle Bookmarks